Would studies evaluating FDA safety profiles and affordability of orphan drugs be of interest to PCORI?

This research question is not within the scope of research that PCORI funds and would be considered non-responsive. PCORI's research awards focus on CER with patient-centered outcomes. Additionally, PCORI does not fund cost-effectiveness studies comparing the costs of drugs and interventions.